VBL Therapeutics Announces Positive Phase 2a Data for VB-111 in Recurrent Thyroid Cancer
December 22, 2014 at 08:32 AM EST
VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company committed to the discovery, development and commercialization ...
